**Recent leadership turnover at the FDA, including Marty Makary’s May 2026 resignation and Kyle Diamantas’s appointment as acting commissioner, has left the permanent position open amid ongoing White House deliberations.** Diamantas’s current role and ties to administration priorities give him a leading position among named contenders, while veterans from the first Trump term such as Brett Giroir and Stephen Hahn remain under consideration for their regulatory experience. Sara Brenner and Grace Graham appear in discussions as internal or policy-focused options. The sizable share priced on no announcement by year-end reflects procedural realities: Senate confirmation timelines, potential post-midterm delays, and the administration’s preference for a slate of senior FDA appointments rather than an immediate solo nomination. With top probabilities clustered closely, the market shows uncertainty over whether the White House will elevate the acting commissioner, select a prior-term figure for continuity, or extend the search to align with broader health policy goals. A formal nomination, Senate hearing schedule, or clear White House signal on preferred criteria could quickly shift odds by clarifying the timeline and frontrunner.